This Month’s Focus: Particle Characterization
Efficient data analysis (EDA): Size, mass and common sense
The third in a series of articles from the IPAC-RS Cascade Impaction Working Group concerning the limitations of metrics commonly used in the assessment of aerodynamic particle size distributions (APSDs) of orally inhaled products (OIPs). The current article takes a broader view to discuss why we make quality control measurements such as inhaler APSD.
Applications of surface analytical techniques in characterization of dry powder formulations
Surface composition and interfacial properties of dry powder particles play a significant role in the processing, structure and functionality of orally inhaled dry powders. Therefore, advanced surface characterization techniques, such as AFM, XPS and ToF-SIMS, are critical to better understanding powder behavior in the early stages of DPI formulation, which may help avoid stability issues later in development.
Cross-Industry Organizations: The Aerosol Society—Bringing academia, research and industry together for more than 30 years
This article previews the 2021 Drug Delivery to the Lungs (DDL) Conference, which will be virtual. The Aerosol Society is also leading the organization of this year’s virtual European Aerosol Conference. The article also discusses The Centre for Doctoral Training in Aerosol Science, a consortium of UK aerosol science researchers and 45 industrial and public sector bodies.
Back Page: Research model provides unexpected findings on causes of thunderstorm asthma and deadly Australian event
The most severe thunderstorm asthma (TA) event reported caused approximately 14,000 people in Melbourne, Australia to seek emergency care for respiratory symptoms and contributed to 10 deaths. The Victorian Grass Pollen Emission Module is being used to study mechanisms for these rare events. Surprisingly, high humidity was not a factor but strong winds, lightning strikes and static electricity due to low humidity may be causes.
Penetration enhancers and mucoadhesives in liquid nasal spray formulations
Propellant and formulation properties for next-generation pMDI products: Measurement, representation and prediction
Cross-industry organizations: Respiratory Drug Delivery 2022: Bringing the respiratory world together in person
Previewing Drug Delivery to the Lungs 2021
January: Reference and Buyer’s Resource
February: Product Development/ Contract Testing
June: Nasal Delivery/Nebulizers
August: Particle Characterization
1155 Northland Drive
St. Paul, MN 55120
Inhalation Article Guidelines
Technical article requirements
The article should be technical and educational, but not promotional. It must be new, not previously published and must be at least 50% different from your previous articles or other articles you are simultaneously developing on the same subject.
All discussions of products or technologies must be in an unbiased, non-promotional, educational manner. If your article discusses products that have been commercialized or are in development, please be aware of the following: Inhalation takes a very limited approach in discussing products, usually listing only product name, delivered drug name and company name, unless a description is provided by the particular company that owns a product, such as in a case study article or product news release. In that way, each company can choose the information it wishes to discuss or disclose about its own products, rather than being discussed by an outside party with no ability to comment prior to publication. However, if an article is a case study, presentation of a novel technology or news article written by the owner company or its representative such as a scientist or consultant, we are happy to consider all information or data they wish to disclose, provided it is presented in a fair-balanced manner. Also, please avoid discussing product or development costs and do not make cost comparisons.
The article should be 2,500-3,500 words and must include at least five references or items for recommended reading.
We encourage images and/or data tables and have space for three or four of them. We’re flexible about that number so let us know if you need more image space. We also like to publish an additional photo or illustration at the beginning of the article. Images should be sent as separate files that meet the following specifications: high resolution, 300 dpi at a size of 7 x 7 inches and in only JPG, TIF or EPS formats.
Please be aware, due to copyrights, if you use figures or tables from articles that have been previously published in other journals, you must obtain permission from those journals in order to use the images. If you are an author on the published article in question, you may still need permission but there should be no fees from the other journal. If you are not an author and the other journal wants to charge you fees for usage, please contact us before proceeding. We do not want authors incurring costs in order to publish in Inhalation and there may be alternate approaches to citing information that could be used. Also, “open journals” do not charge for image use. If you have any questions or concerns, please contact us.
Editorial board review and production
All of our articles are peer-reviewed and must be accepted by our editorial board or a designated reviewer in order to be published. When you send us the article, it will go to a member of the board and we will coordinate communication between you. Once an article is accepted, we handle production and you will see the final article in layout before it goes to print or is published in the digital edition.